In an innovative study, researchers employed CRISPR/Cas9 technology to excise CD5 and CD7 during the production of bispecific CARs, resulting in fratricide-resistant fully human CD5/CD7 bispecific CAR-Ts that exhibit powerful anti-tumor activity against T-cell malignancies 134. This evidence concerns the gene CD5 and neoplasm.